Abstract
We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (n = 24) and plasma (n = 25) samples. The median plasma efavirenz concentration was 3,718 ng/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng/ml (range, 7.3 to 22.3). The CSF/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / cerebrospinal fluid
-
Anti-HIV Agents / pharmacokinetics*
-
Antifungal Agents / pharmacology
-
Area Under Curve
-
Benzoxazines / blood
-
Benzoxazines / cerebrospinal fluid
-
Benzoxazines / pharmacokinetics*
-
Chromatography, High Pressure Liquid
-
Coinfection
-
Cryptococcus neoformans / drug effects
-
Cryptococcus neoformans / growth & development
-
Cyclopropanes
-
HIV / drug effects
-
HIV / growth & development
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
Half-Life
-
Humans
-
Male
-
Meningitis, Cryptococcal / drug therapy*
-
Meningitis, Cryptococcal / microbiology
-
Middle Aged
-
Tandem Mass Spectrometry
Substances
-
Alkynes
-
Anti-HIV Agents
-
Antifungal Agents
-
Benzoxazines
-
Cyclopropanes
-
efavirenz